Sakuranetin (20 mg/kg, intratracheal instillation, 10 μL) reduces inflammation, and reduces respiratory system elastance in an mice acute lung inflammation model induced by LPS[2].
Sakuranetin (20 mg/kg, intratracheal instillation) attenuates airway hyperresponsiveness and inflammation in Ovalbumin induced asthma murine model[5].
| Animal Model: | Acute lung inflammation mice model induced by LPS (5 mg/kg)[2] |
| Dosage: | 20 mg/kg |
| Administration: | intratracheal instillation, 10 μL |
| Result: | Reduced respiratory system elastance.
Decreased LPS-induced blood and pulmonary leukocytes.
Reduced proinflammatory cytokines, markers of M1- and M2-like macrophages, and activation of NF-κB in lung tissue. |
